124.208 - SCHEDULE III -- SUBSTANCES INCLUDED.
124.208 SCHEDULE III -- SUBSTANCES INCLUDED.
1. Schedule III shall consist of the drugs and other substances,
by whatever official name, common or usual name, chemical name, or
brand name designated, listed in this section.
2. Stimulants. Unless specifically excepted or unless listed
in another schedule, any material, compound, mixture, or preparation
which contains any quantity of the following substances having a
stimulant effect on the central nervous system, including its salts,
isomers (whether optical, position, or geometric), and salts of such
isomers whenever the existence of such salts, isomers, and salts of
isomers is possible within the specific chemical designation:
a. Benzphetamine.
b. Chlorphentermine.
c. Clortermine.
d. Phendimetrazine.
3. Depressants. Unless specifically excepted or unless
listed in another schedule, any material, compound, mixture, or
preparation which contains any quantity of the following substances
having a depressant effect on the central nervous system:
a. Any compound, mixture or preparation containing
amobarbital, secobarbital, pentobarbital or any salt thereof and one
or more other active medicinal ingredients which are not listed in
any schedules.
b. Any suppository dosage form containing amobarbital,
secobarbital, pentobarbital or any salt of any of these drugs and
approved by the federal food and drug administration for marketing
only as a suppository.
c. Any substance which contains any quantity of a derivative
of barbituric acid or any salt thereof.
d. Chlorhexadol.
e. Lysergic acid.
f. Lysergic acid amide.
g. Methyprylon.
h. Sulfondiethylmethane.
i. Sulfonethylmethane.
j. Sulfonmethane.
k. Tiletamine and zolazepam or any salt thereof, including
the following:
(1) Some trade or other names for a
tiletamine-zolazepam combination product:
Telazol.
(2) Some trade or other names for tiletamine:
2-(ethylamino)-2-(2-thienyl)-cyclohexanone.
(3) Some trade or other names for zolazepam:
4-(2-fluorophenyl)-6,8-dihydro-1,3,8-
trimethylpyraxolo-[3,4-e] [1,4]-diazepin-
7(1H)-one flupyrazapon.
l. Ketamine, its salts, isomers, and salts of
isomers. Some other names for ketamine:
(+-)-2-(2-chlorophenyl)-2-(methylamino)-
cyclohexanone.
m. Any drug product containing gamma-
hydroxybutyric acid, including its salts, isomers,
and salts of isomers, for which an application is
approved under section 505 of the federal Food,
Drug, and Cosmetic Act.
n. Embutramide.
4. Nalorphine.
5. Narcotic drugs. Unless specifically excepted or unless
listed in another schedule:
a. Any material, compound, mixture, or preparation containing
any of the following narcotic drugs, or their salts calculated as the
free anhydrous base or alkaloid, in limited quantities as set forth
below:
(1) Not more than one point eight grams of codeine per one
hundred milliliters or not more than ninety milligrams per dosage
unit, with an equal or greater quantity of an isoquinoline alkaloid
of opium.
(2) Not more than one point eight grams of codeine per one
hundred milliliters or not more than ninety milligrams per dosage
unit, with one or more active, nonnarcotic ingredients in recognized
therapeutic amounts.
(3) Not more than three hundred milligrams of dihydrocodeinone
(another name: hydrocodone) per one hundred milliliters or not more
than fifteen milligrams per dosage unit, with a fourfold or greater
quantity of an isoquinoline alkaloid of opium.
(4) Not more than three hundred milligrams of dihydrocodeinone
(another name: hydrocodone) per one hundred milliliters or not more
than fifteen milligrams per dosage unit, with one or more active,
nonnarcotic ingredients in recognized therapeutic amounts.
(5) Not more than one point eight grams of dihydrocodeine per one
hundred milliliters or not more than ninety milligrams per dosage
unit, with one or more active, nonnarcotic ingredients in recognized
therapeutic amounts.
(6) Not more than three hundred milligrams of ethylmorphine per
one hundred milliliters or not more than fifteen milligrams per
dosage unit, with one or more active, nonnarcotic ingredients in
recognized therapeutic amounts.
(7) Not more than five hundred milligrams of opium per one
hundred milliliters or per one hundred grams or not more than
twenty-five milligrams per dosage unit, with one or more active,
nonnarcotic ingredients in recognized therapeutic amounts.
(8) Not more than fifty milligrams of morphine per one hundred
milliliters or per one hundred grams, with one or more active,
nonnarcotic ingredients in recognized therapeutic amounts.
b. Any material, compound, mixture, or preparation containing
the narcotic drug buprenorphine, or its salts.
6. Anabolic steroids. Unless specifically excepted in
subsection 7 or unless listed in another schedule, any material,
compound, mixture, or preparation containing any quantity of the
following substances, including their salts, esters, and ethers:
a. 3[beta],17-dihydroxy-5[alpha]-androstane.
b. 3[alpha],17[beta]-dihydroxy-5[alpha]-
androstane.
c. 5[alpha]-androstan-3,17-dione.
d. 1-androstenediol(3[beta],17[beta]-
dihydroxy-5[alpha]-androst-1-ene).
e. 1-androstenediol (3[alpha],17[beta]-
dihydroxy-5[alpha]-androst-1-ene).
f. 4-androstenediol (3[beta],17[beta]-
dihydroxy-androst-4-ene).
g. 5-androstenediol (3[beta],17[beta]-
dihydroxy-androst-5-ene).
h. 1-androstenedione ([5[alpha]]-androst-
1-en-3,17-dione).
i. 4-androstenedione (androst-4-en-3,17-
dione).
j. 5-androstenedione (androst-5-en-3,17-
dione).
k. Bolasterone (7[alpha],17[alpha]-dimethyl-
17[beta]-hydroxyandrost-4-en-3-one).
l. Boldenone (17[beta]-hydroxyandrost-1,4-
diene-3-one).
m. Calusterone (7[beta],17[alpha]-dimethyl-
17[beta]-hydroxyandrost-4-en-3-one).
n. Clostebol (4-chloro-17[beta]-
hydroxyandrost-4-en-3-one).
o. Dehydrochloromethyltestosterone
(4-chloro-17[beta]-hydroxy-17[alpha]-
methylandrost-1,4-dien-3-one).
p. [Delta]1-dihydrotestosterone
(also known as 1-testosterone)(17[beta]-hydroxy-
5[alpha]-androst-1-en-3-one).
q. 4-dihydrotestosterone (17[beta]-hydroxy-
androstan-3-one).
r. Drostanolone (17[beta]-hydroxy-2[alpha]-
methyl-5[alpha]-androstan-3-one).
s. Ethylestrenol (17[alpha]-ethyl-17[beta]-
hydroxyestr-4-ene).
t. Fluoxymesterone (9-fluoro-17[alpha]-
methyl-11[beta],17[beta]-dihydroxyandrost-
4-en-3-one).
u. Formebolone (2-formyl-17[alpha]-methyl-
11[alpha],17[beta]-dihydroxyandrost-1,4-dien-
3-one).
v. Furazabol (17[alpha]-methyl-17[beta]-
hydroxyandrostano[2,3-c]-furazan).
w. 13[beta]-ethyl-17[beta]-hydroxygon-
4-en-3-one.
x. 4-hydroxytestosterone (4,17[beta]-
dihydroxy-androst-4-en-3-one).
y. 4-hydroxy-19-nortestosterone (4,17[beta]-
dihydroxy-estr-4-en-3-one).
z. Mestanolone (17[alpha]-methyl-17[beta]-
hydroxy-5[alpha]-androstan-3-one).
aa. Mesterolone (1[alpha]methyl-17[beta]-
hydroxy-[5[alpha]]-androstan-3-one).
ab. Methandienone (17[alpha]-methyl-
17[beta]-hydroxyandrost-1,4-dien-3-one).
ac. Methandriol (17[alpha]-methyl-
3[beta],17[beta]-dihydroxyandrost-5-ene).
ad. Methenolone (1-methyl-17[beta]-
hydroxy-5[alpha]-androst-1-en-3-one).
ae. 17[alpha]-methyl-3[beta],17[beta]-
dihydroxy-5[alpha]-androstane.
af. 17[alpha]-methyl-3[alpha],17[beta]-
dihydroxy-5[alpha]-androstane.
ag. 17[alpha]-methyl-3[beta],17[beta]-
dihydroxyandrost-4-ene.
ah. 17[alpha]-methyl-4-hydroxynandrolone
(17[alpha]-methyl-4-hydroxy-17[beta]-
hydroxyestr-4-en-3-one).
ai. Methyldienolone (17[alpha]-methyl-
17[beta]-hydroxyestra-4,9(10)-dien-3-one).
aj. Methyltrienolone (17[alpha]-methyl-
17[beta]-hydroxyestra-4,9-11-trien-3-one).
ak. Methyltestosterone (17[alpha]-methyl-
17[beta]-hydroxyandrost-4-en-3-one).
al. Mibolerone (7[alpha],17[alpha]-dimethyl-
17[beta]-hydroxyestr-4-en-3-one).
am. 17[alpha]-methyl-[Delta]1-
dihydrotestosterone (17b[beta]-hydroxy-
17[alpha]-methyl-5[alpha]-androst-1-en-3-one)
(also known as 17-[alpha]-methyl-1-
testosterone).
an. Nandrolone (17[beta]-hydroxyestr-
4-en-3-one).
ao. 19-nor-4-androstenediol
(3[beta],17[beta]-dihydroxyestr-4-ene).
ap. 19-nor-4-androstenediol
(3[alpha],17[beta]-dihydroxyestr-4-ene).
aq. 19-nor-5-androstenediol
(3[beta],17[beta]-dihydroxyestr-5-ene).
ar. 19-nor-5-androstenediol
(3[alpha],17[beta]-dihydroxyestr-5-ene).
as. 19-nor-4-androstenedione (estr-4-
en-3,17-dione).
at. 19-nor-5-androstenedione (estr-5-
en-3,17-dione).
au. Norbolethone (13[beta],17[alpha]-
diethyl-17[beta]-hydroxygon-4-en-3-one).
av. Norclostebol (4-chloro-17[beta]-
hydroxyestr-4-en-3-one).
aw. Norethandrolone (17[alpha]-ethyl-
17[beta]-hydroxyestr-4-en-3-one).
ax. Normethandrolone (17[alpha]-methyl-
17[beta]-hydroxyestr-4-en-3-one).
ay. Oxandrolone (17[alpha]-methyl-
17[beta]-hydroxy-2-oxa-[5[alpha]]-androstan-
3-one).
az. Oxymesterone (17[alpha]-methyl-
4,17[beta]-dihydroxyandrost-4-en-3-one).
ba. Oxymetholone (17[alpha]-methyl-
2-hydroxymethylene-17[beta]-hydroxy-
[5[alpha]]-androstan-3-one).
bb. Stanozolol (17[alpha]-methyl-17[beta]-
hydroxy-[5[alpha]]-androst-2-eno[3,2-c]-
pyrazole).
bc. Stenbolone (17[beta]-hydroxy-2-methyl-
[5[alpha]]-androst-1-en-3-one).
bd. Testolactone (13-hydroxy-3-oxo-13,17-
secoandrosta-1,4-dien-17-oic acid lactone).
be. Testosterone (17[beta]-hydroxyandrost-
4-en-3-one).
bf. Tetrahydrogestrinone
(13[beta],17[alpha]-diethyl-17[beta]-
hydroxygon-4,9,11-trien-3-one).
bg. Trenbolone (17[beta]-hydroxyestr-
4,9,11-trien-3-one).
7. Exclusions -- anabolic steroids. This section shall not
apply to an anabolic steroid that is expressly intended for
administration through implants to cattle or other nonhuman species
and that has been approved for such administration. A person who
prescribes, dispenses, or distributes such steroid for human use
shall be considered to have prescribed, dispensed, or distributed an
anabolic steroid subject to this section. This section shall not
apply to estrogens, progestins, corticosteroids, or
dehydroepiandrosterone.
8. The board by rule may except any compound, mixture, or
preparation containing any stimulant or depressant substance listed
in subsections 2 and 3 of this section from the application of all or
any part of this chapter if the compound, mixture, or preparation
contains one or more active medicinal ingredients not having a
stimulant or depressant effect on the central nervous system, and if
the admixtures are included therein in such combinations, quantity,
proportion, or concentration as to vitiate the potential for abuse of
the substances which have a stimulant or depressant effect on the
central nervous system.
9. Hallucinogenic substances.
a. Dronabinol in sesame oil and encapsulated in a soft
gelatin capsule in a drug product approved for marketing by the
United States food and drug administration.
b. Any drug product in tablet or capsule form containing
natural dronabinol (derived from the cannabis plant) or synthetic
dronabinol (produced from synthetic materials) for which an
abbreviated new drug application (ANDA) has been approved by the
United States food and drug administration under section 505(j) of
the federal Food, Drug, and Cosmetic Act and which references as its
listed drug the drug product identified in paragraph "a".
c. Some other names for dronabinol: (6aR-
trans)-6a, 7, 8, 10a-tetrahydro-6, 6, 9-trimethyl-
3-pentyl-6H-dibenzo [b,d] pyran-1-ol, or
(-)-delta-9-(trans)-tetrahydrocannabinol.
Section History: Early Form
[C73, 75, 77, 79, 81, § 204.208; 82 Acts, ch 1044, § 5] Section History: Recent Form
84 Acts, ch 1013, § 10; 88 Acts, ch 1024, § 2; 91 Acts, ch 8, § 4;
91 Acts, ch 37, §1
C93, § 124.208
94 Acts, ch 1009, §11--13; 95 Acts, ch 6, § 1; 2000 Acts, ch 1140,
§8--10; 2001 Acts, ch 58, §2; 2003 Acts, ch 53, §6, 7; 2007 Acts, ch
8, §10--12; 2008 Acts, ch 1010, §3, 4
Referred to in § 124.201, 124.202, 124.303, 126.2